scholarly journals Proceedings of the 2020 Rare Bone Disease Working Group

JBMR Plus ◽  
2021 ◽  
Vol 5 (S1) ◽  
Keyword(s):  
Bone Disease ◽  
Working Group ◽  
Rare Bone Disease

scholarly journals Contemporary Approaches for Identifying Rare Bone Disease Causing Genes

Bone Research ◽  
2013 ◽  
Vol 1 (4) ◽  
pp. 301-310 ◽  
Author(s):  
Charles R. Farber ◽  
Thomas L. Clemens
Keyword(s):  
Bone Disease ◽  
Rare Bone Disease

scholarly journals The Rare Bone Disease TeleECHO Program: Leveraging Telehealth to Improve Rare Bone Disease Care

2020 ◽  
Vol 18 (4) ◽  
pp. 344-349
Author(s):  
Laura L. Tosi ◽  
Elmer N. Rajah ◽  
Michael H. Stewart ◽  
Austin P. Gillies ◽  
Tracy S. Hart ◽  
...  
Keyword(s):  
Bone Disease ◽  
Rare Bone Disease

scholarly journals International Myeloma Working Group Recommendations for the Treatment of Multiple Myeloma–Related Bone Disease

2013 ◽  
Vol 31 (18) ◽  
pp. 2347-2357 ◽  
Author(s):  
Evangelos Terpos ◽  
Gareth Morgan ◽  
Meletios A. Dimopoulos ◽  
Matthew T. Drake ◽  
Suzanne Lentzsch ◽  
...  
Keyword(s):  
Spinal Cord ◽  
Multiple Myeloma ◽  
Spinal Cord Compression ◽  
Bone Disease ◽  
Working Group ◽  
Cord Compression ◽  
Vertebral Compression Fractures ◽  
Bone Lesions ◽  
Published Data ◽  
International Myeloma Working Group

PurposeThe aim of the International Myeloma Working Group was to develop practice recommendations for the management of multiple myeloma (MM) –related bone disease.MethodologyAn interdisciplinary panel of clinical experts on MM and myeloma bone disease developed recommendations based on published data through August 2012. Expert consensus was used to propose additional recommendations in situations where there were insufficient published data. Levels of evidence and grades of recommendations were assigned and approved by panel members.RecommendationsBisphosphonates (BPs) should be considered in all patients with MM receiving first-line antimyeloma therapy, regardless of presence of osteolytic bone lesions on conventional radiography. However, it is unknown if BPs offer any advantage in patients with no bone disease assessed by magnetic resonance imaging or positron emission tomography/computed tomography. Intravenous (IV) zoledronic acid (ZOL) or pamidronate (PAM) is recommended for preventing skeletal-related events in patients with MM. ZOL is preferred over oral clodronate in newly diagnosed patients with MM because of its potential antimyeloma effects and survival benefits. BPs should be administered every 3 to 4 weeks IV during initial therapy. ZOL or PAM should be continued in patients with active disease and should be resumed after disease relapse, if discontinued in patients achieving complete or very good partial response. BPs are well tolerated, but preventive strategies must be instituted to avoid renal toxicity or osteonecrosis of the jaw. Kyphoplasty should be considered for symptomatic vertebral compression fractures. Low-dose radiation therapy can be used for palliation of uncontrolled pain, impending pathologic fracture, or spinal cord compression. Orthopedic consultation should be sought for long-bone fractures, spinal cord compression, and vertebral column instability.

Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group

2021 ◽  
Vol 22 (3) ◽  
pp. e119-e130 ◽  
Author(s):  
Evangelos Terpos ◽  
Elena Zamagni ◽  
Suzanne Lentzsch ◽  
Matthew T Drake ◽  
Ramón García-Sanz ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Bone Disease ◽  
Working Group ◽  
International Myeloma Working Group

scholarly journals Incorporating the patient perspective in the study of rare bone disease: insights from the osteogenesis imperfecta community

2018 ◽  
Vol 30 (2) ◽  
pp. 507-511 ◽  
Author(s):  
T. Swezey ◽  
B.B. Reeve ◽  
T.S. Hart ◽  
M.K. Floor ◽  
C.M. Dollar ◽  
...  
Keyword(s):  
Osteogenesis Imperfecta ◽  
Bone Disease ◽  
Patient Perspective ◽  
Rare Bone Disease
Sign in / Sign up

Export Citation Format

Share Document